Business Context and Reporting Period
Company: Xtant Medical Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 7, 2024
Event: Entry into a Material Definitive Agreement for a private placement of common stock.
Key Financial Metrics
This filing reports on a capital raise event rather than periodic operating results. Specific metrics include:
- Gross Proceeds: $5.0 million.
- Shares Issued: 7,812,500 shares of common stock.
- Purchase Price: $0.64 per share.
- Use of Proceeds: Working capital and general corporate purposes.
- Operating Metrics: The filing text does not provide revenue, profit, cash flow, margins, or debt figures.
Material Changes
The primary material change is the execution of a Securities Purchase Agreement with an existing institutional investor. This transaction increases the company's share count and capital base. The closing is expected on or about August 9, 2024, subject to customary conditions.
Guidance, Outlook, and Agreements
Management Commentary: The company intends to use net proceeds for working capital and general corporate purposes.
Key Agreements and Restrictions:
- Registration Rights: The company must file a shelf resale registration statement within 30 days of closing and use commercially reasonable efforts to have it declared effective within 60 days (or 90 days if reviewed by the SEC). Failure to meet these deadlines may result in liquidated damages.
- Issuance Restrictions: The company is prohibited from issuing or announcing certain securities for 90 days after the effective date of the resale registration statement. A prohibition on "variable rate transactions" applies for six months.
- Lock-Up Agreements: Directors and executive officers are restricted from selling or disposing of their shares for the later of 90 days from the agreement date or 30 days following the effective date of the resale registration statement.
- Placement Agent: Craig-Hallum Capital Group LLC was engaged as the placement agent and will receive a fee based on a percentage of gross proceeds.
Investor Verification Checklist
- Verify the final closing date and confirmation of the $5.0 million gross proceeds.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and representations.
- Monitor the filing and effectiveness status of the Resale Registration Statement to ensure compliance with the 30-day and 60/90-day deadlines.
- Assess the impact of the 7,812,500 new shares on existing shareholder dilution.
- Confirm the exact amount of offering fees and expenses to determine net proceeds available for working capital.